These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 22036166)

  • 1. Response to "Risk of all-cause and prostate cancer-specific mortality after brachytherapy in men with small prostate size" (Int J Radiat Oncol Biol Phys 2011;79:1318-1322).
    Tunio M; Hashmi A
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1195-6; author reply 1196. PubMed ID: 22036166
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to "Predictors of prostate cancer-specific mortality in elderly men with intermediate-risk prostate cancer treated with brachytherapy with or without external beam radiation therapy" (Int J Radiat Oncol Biol Phys 2009, in press).
    Froehner M; Koch R; Litz RJ; Wirth MP
    Int J Radiat Oncol Biol Phys; 2010 Mar; 76(4):1274. PubMed ID: 20206022
    [No Abstract]   [Full Text] [Related]  

  • 3. 4D analysis of influence of patient movement and anatomy alteration on the quality of 3D U/S-based prostate HDR brachytherapy treatment delivery.
    Milickovic N; Mavroidis P; Tselis N; Nikolova I; Katsilieri Z; Kefala V; Zamboglou N; Baltas D
    Med Phys; 2011 Sep; 38(9):4982-93. PubMed ID: 21978042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In regard to Lee et al.: "Dosimetry and cancer control after low-dose-rate prostate brachytherapy" (Int J Radiat Oncol Biol Phys 2005;61:52-59).
    Shanahan TG; Mueller PW; Maxey RB
    Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):311-2; author reply 312. PubMed ID: 16111606
    [No Abstract]   [Full Text] [Related]  

  • 5. Brachytherapy doses for prostate cancer customized to risk factors: is it more important "how much" or "where"? In regard to Stone et al. (Int J Radiat Oncol Biol Phys 2007;69:1472-1477).
    Oton CA; Oton F
    Int J Radiat Oncol Biol Phys; 2008 Jul; 71(3):962; author reply 962-3. PubMed ID: 18514795
    [No Abstract]   [Full Text] [Related]  

  • 6. Androgen Deprivation (AD) among low-risk and intermediate-risk prostate cancer patients: in regard to Ciezki et al. (Int J Radiat Oncol Biol Phys 2004;60:1347-1350).
    Oton CA
    Int J Radiat Oncol Biol Phys; 2005 May; 62(1):291-2; author reply 292. PubMed ID: 15850937
    [No Abstract]   [Full Text] [Related]  

  • 7. Response to "the impact of pretreatment prostate volume on severe acute genitourinary toxicity in prostate cancer patients treated with intensity-modulated radiation therapy" (Int J Radiat Oncol Biol Phys 2011;79:379-384).
    Oymak E; Onal C
    Int J Radiat Oncol Biol Phys; 2011 Aug; 80(5):1603; author reply 1603-4. PubMed ID: 21740997
    [No Abstract]   [Full Text] [Related]  

  • 8. Prostate brachytherapy as monotherapy: Are there gaps, holes, and islands in the argument? In regard to Wallner et al. (Int J Radiat Oncol Biol Phys 2003;57:1297-1303).
    Rubenstein J
    Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):305; author reply 305-6. PubMed ID: 15629630
    [No Abstract]   [Full Text] [Related]  

  • 9. In regards to Thames et al.: increasing external beam dose for T1-T2 prostate cancer: effect on risk groups. (Int J Radiat Oncol Biol Phys 2006;65:975-981).
    Pickles T; Williams SG
    Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):318-9; author reply 319. PubMed ID: 17189080
    [No Abstract]   [Full Text] [Related]  

  • 10. Prostate postbrachytherapy seed distribution: comparison of high-resolution, contrast-enhanced, T1- and T2-weighted endorectal magnetic resonance imaging versus computed tomography: initial experience: in regard to BLOCH et al. (Int J Radiat Oncol Biol Phys 2007;69:70-78).
    Beaulieu L; Verhaegen F
    Int J Radiat Oncol Biol Phys; 2008 Jul; 71(4):1289; author reply 1289-90. PubMed ID: 18572093
    [No Abstract]   [Full Text] [Related]  

  • 11. Randomized trial of high- and low-source strength (125)I prostate seed implants: In regard to Narayana et al. (Int J Radiat Oncol Biol Phys 2005;61:44-51).
    Moerland MA; Battermann JJ
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):941-2. PubMed ID: 15936582
    [No Abstract]   [Full Text] [Related]  

  • 12. In regard to Anagnostopoulos et al.: In vivo thermoluminescence dosimetry dose verification of transperinal (192)Ir high dose rate brachytherapy using CT-based planning for the treatment of prostate cancer (Int J Radiat Oncol Biol Phys 2003;57:1183-1191).
    Duggan L; Bucci J; Kron T
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):911; author reply 911-2. PubMed ID: 15183495
    [No Abstract]   [Full Text] [Related]  

  • 13. Comment on dose escalation and biochemical failure in prostate cancer: in regard to Kuban et al. (Int J Radiat Oncol Biol Phys 2008;70:67-74).
    Schulz RJ; Kagan AR
    Int J Radiat Oncol Biol Phys; 2008 Jul; 71(4):1288; author reply 1288-9. PubMed ID: 18572089
    [No Abstract]   [Full Text] [Related]  

  • 14. Commentary on dose escalation and biochemical failure in prostate cancer: in regard to Eade et al. (Int. J. Radiat. Oncol. Biol. Phys. 2007;68:682-689).
    Schulz RJ; Kagan AR
    Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):645; author reply 645-6. PubMed ID: 18207038
    [No Abstract]   [Full Text] [Related]  

  • 15. Transperineal injection of hyaluronic acid in anterior perirectal fat to decrease rectal toxicity from radiation delivered with intensity-modulated brachytherapy or EBRT for prostate cancer patients: in regard to Prada et al. (Int J Radiat Oncol Biol Phys 2007;69:95-102.).
    Vordermark D; Guckenberger M; Baier K; Markert K
    Int J Radiat Oncol Biol Phys; 2008 May; 71(1):316-7. PubMed ID: 18406899
    [No Abstract]   [Full Text] [Related]  

  • 16. In regard to D'Amico et al.: predictors of mortality after prostate-specific antigen failure (Int J Radiat Oncol Biol Phys 2006;65:656-660).
    Williams S
    Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1598; author reply 1598-9. PubMed ID: 17126225
    [No Abstract]   [Full Text] [Related]  

  • 17. In regard to "Dose escalation in the radiation therapy of prostate cancer" (Int J Radiat Oncol Biol Phys 2011;80:1289-1291).
    Bowes D; Crook J
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1317-8. PubMed ID: 22385710
    [No Abstract]   [Full Text] [Related]  

  • 18. Radiobiological parameters suitable for modeling individual outcomes cannot be obtained by analyzing heterogeneous population data with homogeneous tumor control model: in regard to D'Souza et al. (Int J Radiat Oncol Biol Phys 2004;58:1540-1548).
    Carlone M; Wilkins D; Raaphorst GP
    Int J Radiat Oncol Biol Phys; 2005 May; 62(1):298-9. PubMed ID: 15850946
    [No Abstract]   [Full Text] [Related]  

  • 19. In regard to Chen et Al. (Int J Radiat Oncol Biol Phys 2007;69:25-31) and Chao et Al. (Int j Radiat Oncol Biol Phys 2007;69:32-40).
    Yaeger TE
    Int J Radiat Oncol Biol Phys; 2008 May; 71(1):317; author reply 317-8. PubMed ID: 18406902
    [No Abstract]   [Full Text] [Related]  

  • 20. Response to "Intraoperative radiotherapy during radical prostatectomy for locally advanced prostate cancer: technical and dosimetric aspects" (Int J Radiat Oncol Biol Phys 2009; in press).
    Thoms J; Bristow R; Warde P; Supiot S
    Int J Radiat Oncol Biol Phys; 2010 Mar; 76(4):1277; author reply 1277. PubMed ID: 20206029
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.